Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaemoon Koh

Showing results (21-30 of 94) with videos related to

Pageof 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 3, 2015
Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areasSehui Kim, Moon-Young Kim, Jaemoon Koh, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 15, 2021
A radiomic signature model to predict the chemoradiation-induced alteration in tumor-infiltrating CD8<sup>+</sup> cells in locally advanced rectal cancerSeung Hyuck Jeon, Yu Jin Lim, Jaemoon Koh, et al.
Inflammatory Bowel Diseases|October 6, 2019
Inactive Rhomboid Protein 2 Mediates Intestinal Inflammation by Releasing Tumor Necrosis Factor-αJee Hyun Kim, Sung Wook Hwang, Jaemoon Koh, et al.
Journal of Cancer Research and Clinical Oncology|August 17, 2022
Predictive role of galectin-3 for immune checkpoint blockades (ICBs) in advanced or metastatic non-small cell lung cancer: a potential new marker for ICB resistanceJung Sun Kim, Soyeon Kim, Jaemoon Koh, et al.
European Journal of Cancer (Oxford, England : 1990)|February 22, 2017
Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomasSehui Kim, Jaemoon Koh, Dohee Kwon, et al.
Acta Neuropathologica Communications|August 31, 2017
The frequency and prognostic effect of TERT promoter mutation in diffuse gliomasYujin Lee, Jaemoon Koh, Seong-Ik Kim, et al.
Annals of Surgical Oncology|October 15, 2015
Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins StatusSu-Jin Shin, Yoon Kyung Jeon, Pil-Jong Kim, et al.
Cell Death & Disease|May 5, 2018
Epithelial cell-derived cytokines CST3 and GDF15 as potential therapeutics for pulmonary fibrosisYoung-Im Kim, Hyun-Woo Shin, Yang-Sook Chun, et al.
International Journal of Molecular Sciences|September 5, 2019
MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell FunctionHyun Kyung Ahn, Sehui Kim, Dohee Kwon, et al.
Cancer Immunology, Immunotherapy : CII|January 9, 2021
Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscapeSeung Geun Song, Sehui Kim, Jaemoon Koh, et al.
Pageof 10

Showing results (21-30 of 94) with videos related to

Sort By:
Pageof 10
European Journal of Cancer (Oxford, England : 1990)|September 3, 2015
Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areasSehui Kim, Moon-Young Kim, Jaemoon Koh, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 15, 2021
A radiomic signature model to predict the chemoradiation-induced alteration in tumor-infiltrating CD8<sup>+</sup> cells in locally advanced rectal cancerSeung Hyuck Jeon, Yu Jin Lim, Jaemoon Koh, et al.
Inflammatory Bowel Diseases|October 6, 2019
Inactive Rhomboid Protein 2 Mediates Intestinal Inflammation by Releasing Tumor Necrosis Factor-αJee Hyun Kim, Sung Wook Hwang, Jaemoon Koh, et al.
Journal of Cancer Research and Clinical Oncology|August 17, 2022
Predictive role of galectin-3 for immune checkpoint blockades (ICBs) in advanced or metastatic non-small cell lung cancer: a potential new marker for ICB resistanceJung Sun Kim, Soyeon Kim, Jaemoon Koh, et al.
European Journal of Cancer (Oxford, England : 1990)|February 22, 2017
Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomasSehui Kim, Jaemoon Koh, Dohee Kwon, et al.
Acta Neuropathologica Communications|August 31, 2017
The frequency and prognostic effect of TERT promoter mutation in diffuse gliomasYujin Lee, Jaemoon Koh, Seong-Ik Kim, et al.
Annals of Surgical Oncology|October 15, 2015
Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins StatusSu-Jin Shin, Yoon Kyung Jeon, Pil-Jong Kim, et al.
Cell Death & Disease|May 5, 2018
Epithelial cell-derived cytokines CST3 and GDF15 as potential therapeutics for pulmonary fibrosisYoung-Im Kim, Hyun-Woo Shin, Yang-Sook Chun, et al.
International Journal of Molecular Sciences|September 5, 2019
MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell FunctionHyun Kyung Ahn, Sehui Kim, Dohee Kwon, et al.
Cancer Immunology, Immunotherapy : CII|January 9, 2021
Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscapeSeung Geun Song, Sehui Kim, Jaemoon Koh, et al.
Pageof 10